NCT02420665 is a EARLY_PHASE1 clinical trial of Proflavine in Cervical Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT02420665?

NCT02420665 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT02420665?

Interventions in NCT02420665: Proflavine, HRME Imaging, Phone Call, Colposcopy, Acetic Acid.

What condition does NCT02420665 study?

NCT02420665 studies Cervical Cancer.

Is NCT02420665 still recruiting?

NCT02420665 is currently completed. Last updated 28 May 2021.

Last reviewed 2021-05-28 · How we verify

NCT02420665

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia

Completed EARLY_PHASE1 Last updated 28 May 2021

What this trial tests

EARLY_PHASE1 trial testing Proflavine in Cervical Cancer in 50 participants. Completed in 14 May 2021.

Timeline

23 September 2015

Primary endpoint
14 May 2021

14 May 2021

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	50
Start date	23 September 2015
Primary completion	14 May 2021
Estimated completion	14 May 2021
Sites	2 locations across United States

Drugs / interventions tested

Proflavine — full drug profile →
HRME Imaging
Phone Call
Colposcopy
Acetic Acid (ACETIC ACID) — full drug profile →

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

21 and older, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to compare a type of imaging called high-resolution microendoscopy (HRME) for detecting abnormal tissue in the cervix to the standard of care, which is visual inspection with acetic acid (VIA) with a colposcopy procedure. Researchers also want to learn if HRME images can show the difference between cancerous tissue and normal cervical tissue.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

In vivo imaging of cervical precancer using a low-cost and easy-to-use confocal microendoscope.
Tang Y, Kortum A, Parra SG, Vohra I, et al · · 2020 · cited 14× · PMID 32010516 · DOI 10.1364/boe.381064

Verify or expand the search:

Other trials of Proflavine

Trials testing the same drug.

NCT05396781 — Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening · Phase 2 · completed
NCT02714439 — Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley · EARLY_PHASE1 · terminated
NCT02206048 — Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix · NA · completed
NCT01269190 — Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery · NA · recruiting

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02420665 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 28 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02420665.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing